Prolia (Denosumab) and Tadalafil Interaction: Safety, Risks, and Clinical Guidance

Denosumab (brand name Prolia for osteoporosis; also marketed as Xgeva at a higher dose for oncologic bone disease) is a monoclonal antibody given by subcutaneous injection every six months. Tadalafil (brand name Cialis, also available generically) is a small-molecule PDE5 inhibitor taken daily at low dose or as-needed at higher dose for erectile dysfunction or benign prostatic hyperplasia. These two drugs are structurally, metabolically, and pharmacologically unrelated, and this page addresses only the Prolia (osteoporosis-dose) formulation of denosumab paired with tadalafil.

Direct answer: There is no known pharmacokinetic interaction between denosumab and tadalafil, based on their FDA labels and their non-overlapping metabolic pathways. Denosumab is cleared by the reticuloendothelial system and does not involve cytochrome P450 enzymes; tadalafil is metabolized mainly by hepatic CYP3A4. Neither the Prolia label nor the Cialis label lists the other drug as an interacting agent. The one area requiring clinical attention is not a drug-drug interaction in the classic sense but an indirect, unproven physiologic overlap: denosumab-associated hypocalcemia and tadalafil-associated vasodilation could theoretically compound to cause lightheadedness in a susceptible patient, though this has not been documented in the published literature reviewed here.

Why this combination comes up in practice

Men with osteoporosis or low bone mass frequently also have erectile dysfunction or BPH, since age, hypogonadism, and vascular disease raise the risk of all three conditions together. This overlap is a plausible clinical scenario rather than a rare edge case, but exact co-prevalence figures for this specific pair of conditions were not verified against a primary source for this draft and should not be cited as precise statistics without checking the original epidemiologic literature.

The FDA label for Prolia does not list tadalafil or any PDE5 inhibitor as a contraindicated or interacting medication, according to its prescribing information. The Cialis label does not warn about co-administration with monoclonal antibodies, according to its prescribing information. Absence of a listed interaction is meaningful evidence but not proof of safety in every individual patient; it reflects what has been studied and reported to date.

Why the metabolic pathways do not overlap

Denosumab is a fully human IgG2 monoclonal antibody that binds RANK ligand (RANKL). Like other therapeutic proteins, it is broken down into peptides and amino acids by the reticuloendothelial system rather than by liver enzymes, per its prescribing information. It has no meaningful interaction with cytochrome P450 enzymes or drug transporters.

Tadalafil is metabolized predominantly by CYP3A4, per its prescribing information. Drugs that strongly inhibit or induce CYP3A4 (such as ketoconazole, ritonavir, or rifampin) can meaningfully raise or lower tadalafil blood levels; the magnitude of these known interactions is documented in the Cialis label itself and should be checked there rather than relied on from secondary summaries. Denosumab has no CYP3A4 activity of any kind, so it cannot raise or lower tadalafil levels by this mechanism.

This is consistent with general regulatory guidance on drug interaction testing, which notes that large protein therapeutics are not expected to cause cytochrome P450-mediated interactions because they do not enter hepatocyte metabolic pathways. This is a general regulatory principle about protein drugs, not a study of denosumab and tadalafil specifically together.

The one area that deserves attention: calcium and blood pressure

Tadalafil causes mild vasodilation through PDE5 inhibition, which can produce small reductions in blood pressure; the Cialis label describes this as generally modest but clinically relevant in combination with alpha-blockers or other antihypertensives.

Denosumab's principal systemic risk is hypocalcemia, caused by abrupt suppression of osteoclast-mediated bone resorption. The Prolia label carries a warning about hypocalcemia, particularly in patients with renal impairment, and requires adequate calcium and vitamin D intake before and during treatment. Severe hypocalcemia can cause muscle cramping, paresthesias, QT prolongation, and in rare cases hypotension.

The theoretical concern is that a patient who develops symptomatic hypocalcemia after a denosumab dose, and who is also taking tadalafil, could experience an additive hemodynamic effect (hypocalcemia-related hypotension plus tadalafil-related vasodilation) leading to dizziness or syncope. This is a plausible physiologic overlap, not an established interaction. No published case series specific to this combination was located to confirm or quantify the risk, and this claim should be treated as a monitoring consideration rather than a documented adverse event pattern.

Because of this, ensuring calcium and vitamin D adequacy before each denosumab injection matters regardless of tadalafil use, and it becomes a slightly higher priority in patients also taking a vasoactive medication.

Evidence-status interaction assessment

What the labels actually require, separately

Denosumab (Prolia): the label calls for adequate calcium and vitamin D supplementation and monitoring of serum calcium, particularly in patients with renal impairment, before and during treatment. This requirement exists independent of any other medication the patient takes, including tadalafil.

Tadalafil (Cialis): the label carries an absolute contraindication with organic nitrates (nitroglycerin, isosorbide mononitrate) because of the risk of severe, potentially fatal hypotension, and recommends caution or dose reduction with alpha-blockers, strong CYP3A4 inhibitors, and in renal or hepatic impairment. None of these tadalafil warnings involve denosumab.

Bone effects of PDE5 inhibitors: an open question, not a clinical recommendation

Some preclinical and observational research has explored whether PDE5 inhibitors like tadalafil might influence bone metabolism through nitric oxide/cGMP signaling in osteoblasts, and whether PDE5 inhibitor users have different fracture rates than non-users. This is an active research question, not a settled finding, and no prospective clinical trial has evaluated tadalafil as a bone-protective therapy. It would be inaccurate to tell a patient that tadalafil helps their bones, and it would equally be inaccurate to suggest it harms them. The specific studies referenced in earlier drafts of this topic could not be verified against a confirmed primary source for this revision and have been removed rather than cited with an unverified locator.

Renal impairment changes both drugs' management, separately

Patients with significant renal impairment (roughly eGFR under 30 mL/min) are at higher risk of denosumab-associated hypocalcemia and require closer calcium monitoring per the Prolia label. Separately, the Cialis label recommends dose limits for tadalafil in patients with reduced creatinine clearance and advises against the as-needed higher-dose regimen in severe renal impairment. These are two independent dose and monitoring adjustments driven by the same underlying kidney disease, not a drug-drug interaction between denosumab and tadalafil.

Other interactions that matter more than this pairing

For denosumab: concurrent immunosuppressants (corticosteroids, methotrexate, biologic agents) may raise infection risk, an established label warning. Stopping denosumab without a planned transition to another antiresorptive (commonly a bisphosphonate) has been associated with rebound vertebral fractures, and current guideline-based practice is to plan this transition carefully rather than simply discontinue denosumab. This is a guideline-level recommendation, and patients should not stop denosumab on their own.

For tadalafil: the contraindication with nitrates is absolute. Alpha-blockers can produce additive blood pressure lowering, and the label recommends starting at a lower tadalafil dose in that setting. Strong CYP3A4 inhibitors (ritonavir, ketoconazole, clarithromycin) raise tadalafil exposure, and strong inducers (rifampin, carbamazepine, phenytoin) can reduce its effect. None of these involve denosumab.

What is established, what is plausible, what is not established

Established: denosumab and tadalafil use separate elimination pathways with no shared metabolic enzymes; neither FDA label lists the other drug as an interacting agent; each drug carries its own independent, well-documented set of monitoring requirements and true interactions with other medications.

Plausible but unproven: an additive hemodynamic effect between hypocalcemia-related hypotension and tadalafil-related vasodilation in a patient who develops significant hypocalcemia; a possible skeletal benefit of PDE5 inhibitors suggested by preclinical and observational data.

Not established: any pharmacokinetic interaction between the two drugs; any need to adjust the dose of either drug because of the other; any documented case of harm from co-administration in the published literature reviewed for this page.

When to involve a specialist

Consider endocrinology or bone-specialist input for a patient with serum calcium below normal range before a scheduled denosumab dose, significant renal impairment, a history of osteonecrosis of the jaw or atypical femoral fracture, or concurrent high-dose glucocorticoid therapy. These triggers relate to denosumab management generally, not specifically to tadalafil co-use. A patient experiencing dizziness, fainting, chest pain, or severe muscle cramping after starting either medication should seek urgent medical evaluation rather than wait for a routine follow-up.

This page describes general pharmacology and labeling information and is not a substitute for individualized advice from the prescribing clinician or pharmacist, who can review a patient's full medication list, kidney function, and calcium status.